



Liquid Biopsy in Cancer

Guest Editors:

Prof. Dr. Fabio Puglisi

1. Department of Medical Oncology, IRCCS, CRO di Aviano, National Cancer Institute, Aviano, Italy

2. Department of Medicine, University of Udine, 33100 Udine, Italy

Dr. Lorenzo Gerratana

1. Department of Medical Oncology, IRCCS, CRO di Aviano, National Cancer Institute, Aviano, Italy

2. Department of Medicine, University of Udine, 33100 Udine, Italy

Deadline for manuscript submissions:

closed (31 December 2020)

Message from the Guest Editors

Precision medicine is becoming the new paradigm in healthcare as it enables treatment optimization, a potential reduction in side effects, and better resources allocation. Liquid biopsy is the cornerstone of this revolution since it provides real-time prognostic and predictive information for advanced cancer patients without the analytical and procedural drawbacks of tissue biopsy.

Several technologies are comprised under the umbrella term of “liquid biopsy”, each with its strengths and peculiarities. In particular, circulating tumor DNA (ctDNA) together with circulating tumor cells (CTCs) and microvesicles are gaining momentum as promising markers for early disease characterization and longitudinal monitoring for resistance detection.

This Special Issue is aimed at summarizing both analytical developments and clinical evidence regarding the application of liquid biopsy across the major cancer types, with a special focus on its clinical utility and how its deployment will ultimately lead to the growing personalization of cancer care.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)